Lonza Signs Agreement to Divest Specialty Ingredients Business to Bain Capital and Cinven

Basel, Switzerland, 8 February 2021 – Lonza has entered into a definitive agreement with Bain Capital and Cinven to acquire Lonza's Specialty Ingredients business and operations for an enterprise value of CHF 4.2 billion.

Both Bain Capital and Cinven have strong experience in the industrials sector and an established track record of successful investments in portfolio companies. The two private equity bidders showed strong and sustained interest since the beginning of the official sale process, thereby confirming that they are the best home for the business and the right transaction partner for Lonza.

Lonza's Specialty Ingredients business operates across 17 manufacturing sites globally and has approximately 2,800 permanent employees. The business is a leading provider of microbial control solutions for Professional Hygiene and Personal Care products. It also offers the custom development and manufacturing of specialty chemicals and composites to support the electronics, aerospace, food and agrochemical industries.

The transaction is expected to close in H2 2021, subject to customary closing conditions. The ownership transfer process is expected to be smooth. Bain Capital and Cinven have confirmed that high standards of service delivery and quality for customers will remain a priority following closing.

BofA Securities and UBS are acting as joint financial advisors to Lonza.

About Lonza 

Lonza is the preferred global partner to the pharmaceutical, biotech and nutrition markets. We work to prevent illness and enable a healthier world by supporting our customers to deliver new and innovative medicines that help treat a wide range of diseases. We achieve this by combining technological insight with world-class manufacturing, scientific expertise and process excellence. These enable our customers to commercialize their discoveries and innovations in the healthcare sector. 

Founded in 1897 in the Swiss Alps, today Lonza operates across three continents. With approximately 14,000 full-time employees, we are built from high-performing teams and of individual talent who make a meaningful difference to our own business, as well as to the communities in which we operate. The company generated sales of CHF 4.5 billion in 2020 with a CORE EBITDA of CHF 1.4 billion. Find out more at 

Follow @Lonza on LinkedIn 
Follow @LonzaGroup on Twitter

Lonza Contact Details 

Dirk Oehlers 
Investor Relations 
Lonza Group Ltd 
Tel 41 61 851 4927 

Dr. Sanna Fowler 
Head of External Communications 
Lonza Group Ltd 
Tel 41 61 316 8929 

Victoria Morgan 
Head of Corporate Communications 
Lonza Group Ltd 
Tel 41 61 316 2283 

Additional Information and Disclaimer 

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual. 

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.